📣 We’ve successfully randomised 1,645 patients to IP7-PACIFIC! RCT1️⃣ bpMRI vs mpMRI RCT2️⃣ image-fusion vs visual estimation targeting Top recruiters in October 🏆 1st – Imperial 🥈 Joint 2nd – Cumberland & St Peter’s Top total recruiters 🏆 Imperial - 346 🥈 Southend - 338

The medium term effectiveness of MRI-directed dx pathway in 📈 GG≥2, 📉 GG1 and 🛑 redundant biopsies. PSAD-based PSA threshold for re-referral (20%+ from initial PSA if baseline PSAD >0.12, or PSA when their PSAD reaches 0.12) is safe. 👨‍🏫@LondonProstate1 @TaimurShah

The medium-term oncological safety of MRI-led prostate cancer diagnostic pathway is unclear. We followed up 1266 patients and summarised our findings into 3 key messages. @IP_London @EUplatinum Read full paper for free: https://t.co/d7Ma9cUBXr

🚨 The IP14-FOCUS trial has launched and recruited its first patients! 🚨 A phase 2 cohort study investigating the use of intra-operative contrast-enhanced ultrasound during focal HIFU, cryotherapy, and IRE @AJWLight @LondonProstate1 @TaimurShah @ecmc @NIHRresearch

🚨 NEW paper @EUplatinum 🚨 5-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the #RAPID MRI-directed Prostate Cancer Diagnostic Pathway Led by @cut_tt_chase @LondonProstate1 @TaimurShah Read for free! https://t.co/YyvvThEgXj 1/4

Missed out on #BAUS25? Fear not...we have produce a series of infographics summarising each sub-specialty and key topics / discussion points across the three-day conference. Next up, we take a look at the sections of #Oncology, #FunctionalReconstuctiveUrology and #SASandTrust

Influence of a surgeon’s exposure to operating room turnover delays on patient outcomes ➡️ https://t.co/ancE0eN5yH In this prospective study, a 3.3% (95% c.i. 0.6% to 5.6%) increase in the rate of major adverse events was observed when a surgeon experienced a delay in operating

📢Excited to share our new publication "Comparison of Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) and Prostate Imaging after Focal Ablation (PI-FAB) for Detecting Recurrent Prostate Cancer at Prostate MRI"

Nice. Looks like better overall accuracy for TARGET scoring post focal therapy compared to PI-FAB. @IP_London @FocalSociety @AJWLight @TaimurShah

@ethansgrumps @GaryHooker16 @ProstateUK Reposting the paper here:

We then wondered if we could look at real NHS data to see how common incidents of harm really were (not in trials but in real life) and compare it to what happened a few years ago. Thank you to @TaimurShah & Nick Burns Cox we looked at anonymous data from >16k NHS patients...🧵

The role of Multiparametric Magnetic Resonance Imaging-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FOcal RECurrent Assesment and Salvage Treatment Trial by @AJWLight Watch all our Spotlights here: https://t.co/PNeAze6nnS

💬 #IP5MATTER trial reports patients with advanced (metastatic) are willing to accept additional cytoreductive radiotherapy, surgery, ablation & SABR for survival benefits - in particular those that preserve urinary function and reduced fatigue @EUplatinum @EurUrolOncol

Great to round off #BAUS24 with four abstracts in the prostate cancer session, plus a best poster prize for our work on local salvage treatments in radiorecurrent disease! Thanks to @IP_London @TaimurShah @LondonProstate1!

Spent 2 weeks observing HIFUs, Cryos and TPBs at @IP_London under the mentorship of @LondonProstate1 @TaimurShah. Courtesy of @Uroweb EUSP Fellowship grant. @johannboaz @DrGaganGautam @DrP_Ahluwalia @usioffice

Great to welcome Vincent Tang & Craig Jones from the urology department in Stockport Hospital observing focal therapy for prostate cancer Focal HIFU in Northwest England soon! @IP_London @prost8uk @SonablateCorp @TaimurShah @vtang77 @craig_m_jones @HillUrology @StockportNHS

Proud that the Center for Image Guided Surgery, #focaltherapy and #AI for #ProstateCancer at @USC_Urology is presenting 14 abstracts at the #AUA24 Strong work by the fellows and team Follow @lorenzormc and @KanekoMasatomo for in depth discussion during the presentations

Results of a non-randomised, multi-centre, large study in >3k patients from ⁦@AFUrologie⁩ comparing radical prostatectomy (RP) and HIFU (not focal) presented at #AUA24 The HIFU patients were older HIFU was non-inferior to RP HIFU licensed in France after this study

Congratulations #IP2ATLANTA 🎉4️⃣0️⃣0️⃣🎉 patients recruited! Open across 🏴󠁧󠁢󠁥󠁮󠁧󠁿🏴󠁧󠁢󠁷󠁬󠁳󠁿 for patients seeking additional treatments to their prostate cancer deposits following a new diagnosis of prostate cancer 🔗 https://t.co/9NNFxD4hoH

@TaimurShah @KabirOlaAli @LondonProstate1 @philcornford Totally agree. Some men will always demand to be treated and even if we start with AS for all, 60% will undergo radical treatment (ProtecT). The key is to treat effectively and gently - not just wait & survey then fire a bazooka at the gland.